Dermira, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $299,000 | $1.1M | $22.6M | $7.3M | $7.3M | — |
| Operating income | −$214.0M | −$300.3M | −$90.6M | −$79.6M | −$31.7M | −$22.3M |
| Net income | −$59.3M | −$29.5M | −$89.1M | −$78.4M | −$31.9M | −$22.4M |
| Total assets | $344.3M | $560.8M | $312.6M | $221.9M | $178.2M | $26.9M |
| Total liabilities | $353.4M | $411.1M | $65.2M | $36.5M | $24.6M | $17.1M |
| Equity | −$9.0M | $149.6M | $247.4M | $185.5M | $153.6M | −$49.8M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 41.8M | 35.7M | 30.0M | 30.0M | 24.7M | 901,308 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −71565.9%
- Net margin
- −19817.4%
- Return on equity
- 655.5%
- Return on assets
- −17.2%
- Return on capital (ROCE)
- −70.0%
- Liabilities / assets
- 102.6%
- Debt / equity
- —
- Book value / share
- $-0.22
- Revenue growth (YoY)
- −72.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -5.60distress
- Accruals / assets
- 44.7%high accruals
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 6 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nunn Jason RaleighDirector | Feb 20, 2020 | D | 6,000 | $18.75 |
| Guggenhime AndrewOfficer — CFO | Feb 20, 2020 | D | 41,951 | $18.75 |
| Mcdade MarkDirector | Feb 20, 2020 | D | 6,000 | $18.75 |
| Fust Matthew KDirector | Feb 20, 2020 | D | 5,051 | $18.75 |
| Lyons-Williams LoriOfficer — Chief Commercial Officer | Feb 20, 2020 | D | 25,401 | $18.75 |
| Aurora Daljit SinghOfficer — Chief Scientific Affairs Off | Feb 20, 2020 | D | 30,089 | $18.75 |
| Horan ChristopherOfficer — Chief Technical Ops Officer | Feb 20, 2020 | D | 21,400 | $18.75 |
| Bauer Eugene AOfficer — Chief Medical Officer | Feb 11, 2020 | Gift | 12,924 | $0.00 |
| Craves Fred BDirector | Feb 20, 2020 | D | 6,000 | $18.75 |
| Ringo William RDirector | Feb 20, 2020 | D | 6,000 | $18.75 |
| Wiggans Thomas GOfficer — CEO & Chairman of the Board | Feb 5, 2020 | Gift | 27,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 20, 2020
- Entered a material agreement · Other material eventJan 10, 2020
- Director / officer changeNov 13, 2019
- Results of operationsNov 5, 2019
- Other material eventOct 9, 2019
- Results of operationsAug 7, 2019
- Other material eventJun 25, 2019
- Shareholder voteJun 10, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 16, 2021
- SC 13G/AMar 9, 2020
- 15-12BMar 2, 2020
- EFFECTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
- 4PRIMARY DOCUMENTFeb 24, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.